platoseedplatoseed
Using the immune system to cure disease
Parallel Bio is pioneering human-first drug discovery by creating the first map of human biology. Using groundbreaking biological and computational tools that track real clinical outcomes, the company generates data that enable earlier, more reliable decisions about disease biology and drug development. Parallel Bio’s platform overcomes the core limitations of traditional animal testing, which fails to encapsulate the complexity of human biology. The company is building internal pipelines of novel disease targets and drug candidates in both cancer and autoimmune disease, while collaborating with pharmaceutical companies to evaluate therapies directly in human systems to reduce the cost and risk of clinical trials. Based in San Francisco, the company was founded in 2021 by two of the world’s leading experts in replacing animal models with human-first platforms.
Parallel Bio reimagines drug discovery by mapping human biology at population scale, using human data and computational tools to accelerate target discovery, IND timelines, and cost reduction. Their platform focuses on human-first biology and an end-to-end automation flywheel to generate large-scale human data for drug development.
The platform charts the landscape of human biology to support drug discovery from disease target discovery to IND in a fraction of traditional time and cost. It leverages a growing biobank of patient samples and proprietary data generated through closed-loop automation to continuously map human biology, enabling disease-specific precision insights, patient stratification, and rapid, human-centric drug development.
Who it’s for: Biotech/pharma companies seeking faster, human-relevant drug discovery; enterprises pursuing precision medicine and patient stratification; organizations needing large-scale human biology data for target validation and IND preparation.
Evidence of partnerships with Fortune 500 companies; multiple compounds tested; Phase 1 trial informed by data; claims of speed and cost advantages; ongoing hiring/reading of about Careers/Press sections.
Robert is a co-founder and CEO of Parallel Bio. Previously he was Director of Strategy & Research Development at Stanford University where he oversaw a $100M scientific portfolio and ran 8 large-scale R&D programs. He also worked in global health and ran vaccine programs with GSK, the NIH, and the Danish government. He completed his postdoctoral training at Stanford, holds a PhD from the University of Pittsburgh, and a BS from the University of Illinois.
Juliana is a co-founder and the CSO of Parallel Bio. She previously worked at System1 Biosciences managing R&D brain organoid drug discovery teams and has extensive experience developing mini-organ systems to better model human disease and discover new drugs.
PipeBio is a SaaS bioinformatics platform to develop antibody drugs.
Discovering the true signals of disease to power life-changing drugs.
